Related Experiment Videos
Continuous subcutaneous insulin infusion does not provoke significant acute-phase response.
Diabetes Care
|January 1, 1986
Summary
Continuous subcutaneous insulin infusion (CSII) does not appear to cause an acute-phase reaction in diabetic patients. This suggests CSII is unlikely to increase the risk of reactive systemic amyloidosis.
Area of Science:
- Endocrinology
- Immunology
- Nephrology
Background:
- C-reactive protein (CRP) and serum amyloid A protein (SAA) are key acute-phase reactants.
- Diabetes mellitus is a chronic condition requiring careful management.
- Reactive systemic amyloidosis is a potential complication of chronic inflammation.
Purpose of the Study:
- To investigate whether continuous subcutaneous insulin infusion (CSII) triggers an acute-phase reaction in diabetic patients.
- To assess the levels of CRP and SAA in diabetic patients on different insulin therapies.
- To evaluate the potential risk of CSII in predisposing patients to reactive systemic amyloidosis.
Main Methods:
- Measurement of C-reactive protein (CRP) and serum amyloid A protein (SAA) levels.
- Study included 62 diabetic patients attending regular clinic appointments.
- Patients were categorized into groups: CSII, conventional insulin therapy (CIT), diet only, and diet with oral hypoglycemic agents.
Main Results:
- CRP and SAA levels were measured in 62 diabetic patients.
- Levels of CRP and SAA were similar across all treatment groups (CSII, CIT, diet, diet + oral agents).
- Measured protein levels were predominantly within the normal range.
Conclusions:
- Continuous subcutaneous insulin infusion (CSII) does not provoke an acute-phase reaction in diabetic patients.
- CSII is unlikely to predispose diabetic patients to reactive systemic amyloidosis.
- While caution is advised with new treatments, CSII appears safe regarding acute-phase response.